ScoreWhy is Sanara MedTech, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
The company has declared Negative results for the last 4 consecutive quarters
- ROCE(HY) Lowest at -25.78%
- DEBT-EQUITY RATIO (HY) Highest at 80.49 %
- INTEREST(Q) Highest at USD 1.79 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -45.97%, its profits have fallen by -63.2%
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 2.06% over the previous quarter and collectively hold 14.1% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -45.97% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sanara MedTech, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sanara MedTech, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sanara MedTech, Inc.
-40.04%
-0.64
58.68%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
50.13%
EBIT Growth (5y)
-3.33%
EBIT to Interest (avg)
-6.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.63
Sales to Capital Employed (avg)
1.23
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.10%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.15
EV to EBIT
-32.29
EV to EBITDA
-73.36
EV to Capital Employed
4.78
EV to Sales
3.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-14.81%
ROE (Latest)
-36.01%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Bearish
Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 3.64 MM
OPERATING PROFIT MARGIN(Q)
Highest at 4.26 %
RAW MATERIAL COST(Y)
Fallen by -4.36% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 3.66 times
NET SALES(Q)
At USD 25.83 MM has Grown at 28.14%
OPERATING PROFIT(Q)
Highest at USD 1.1 MM
PRE-TAX PROFIT(Q)
Highest at USD -2 MM
NET PROFIT(Q)
Highest at USD -2 MM
-15What is not working for the Company
ROCE(HY)
Lowest at -25.78%
DEBT-EQUITY RATIO
(HY)
Highest at 80.49 %
INTEREST(Q)
Highest at USD 1.79 MM
Here's what is working for Sanara MedTech, Inc.
Operating Cash Flow
Highest at USD 3.64 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit Margin
Highest at 4.26 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Sales
At USD 25.83 MM has Grown at 28.14%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 1.1 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -2 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -2 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 3.66 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -4.36% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Sanara MedTech, Inc.
Interest
At USD 1.79 MM has Grown at 36.02%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 80.49 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Interest
Highest at USD 1.79 MM
in the last five periods and Increased by 36.02% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
